Florence Healthcare Launches SiteLink on AWS Marketplace, Extending its Clinical Trial Operations Platform Capabilities to Cloud
ATLANTA, GEORGIA / ACCESS Newswire / October 28, 2025 / Florence Healthcare, the leading clinical trial platform connecting pharmaceutical sponsors and research sites worldwide, announced today that SiteLink, a key offering of Florence's Trial Operations Platform, is now available in AWS Marketplace.
SiteLink accelerates study startup and enables real-time document distribution, monitoring, and data exchange with study sites, addressing the critical digital divide in clinical trials. With only 30% of global research sites currently using digital workflows, SiteLink helps bridge this gap by automating sponsor-site operational workflows.
Bringing the Florence Trial Operations Platform Benefits to AWS
As a core component of Florence's Trial Operations Platform, SiteLink delivers the same proven results that have made Florence the #1 clinical trial management solution for six consecutive years.
The platform enables:
Faster Startup: Up to 70% faster study activation timelines through automated feasibility, site selection, and document exchange workflows.
Increased Efficiency: Significant operational cost reduction by automating critical sponsor-site workflows.
Reduced Risk: Improved eTMF QA pass rates from 65% to 98.7% with built-in compliance checks.
"AWS customers represent some of the most innovative companies in life sciences, and they deserve access to the most advanced clinical trial technology available," said Chad Garrett, Chief Revenue Officer at Florence Healthcare. "By making SiteLink available through AWS Marketplace, we're extending our Trial Operations Platform capabilities; enabling sponsors and CROs to digitize site operations and gain comprehensive portfolio visibility."
Powered by AI and Built for Scale
SiteLink leverages Florence's AI-powered workflows and risk-based intelligence to deliver early risk detection, automated compliance checks, and real-time operational insights. The solution maintains full alignment with FDA, EMA, HIPAA, GDPR, EU Annex 11, ICH E6 (R3), and GCP standards.
About Availability
SiteLink is now generally available in AWS Marketplace. For more information about Florence Healthcare, visit www.florencehc.com
About Florence Healthcare
Florence is a purpose-built platform that connects sponsors and sites to accelerate clinical trials, improve operational capacity, and reduce risk. Designed for scale, Florence streamlines workflows, enhances collaboration, and delivers real-time visibility across studies, empowering research teams to move faster, stay inspection-ready, and increase trial throughput with fewer resources.
CONTACT:
Seema Sheth-Voss
seema.shethvoss@florencehc.com
(888) 829-0896
SOURCE: Florence Healthcare
View the original press release on ACCESS Newswire
Florence Healthcare
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Investment Firm Alpha Star invests 1 million USD in AI Art Authentication Company Art Recognition29.10.2025 12:00:00 EET | Press release
ZURICH, SWITZERLAND / ACCESS Newswire / October 29, 2025 / Art Recognition , the Swiss pioneer in AI art authentication, is delighted to announce a new strategic partnership with Alpha Star , a leading Luxembourg-based investment fund with a strong track record of supporting innovative companies in the art market. This collaboration marks an important milestone as Alpha Star becomes Art Recognition's anchor investor. The partnership will accelerate Art Recognition's growth and strengthen its position as a trusted technology partner for the art world, helping bring greater transparency, confidence, and innovation to art authentication. "We are thrilled to welcome Alpha Star as a key partner on our journey," said Carina Popovici, CEO and Founder of Art Recognition. "Their confidence in our technology and vision is a strong endorsement of the role AI will play in shaping the future of the art world." "We are excited to support Art Recognition in its mission to bring cutting-edge AI techno
Ecological Threat Report 2025: Extreme Wet-Dry Seasons Emerge as Critical Conflict Catalyst29.10.2025 07:00:00 EET | Press release
Approximately 2 billion people - one quarter of humanity - now live in regions experiencing moderate to severe increases in seasonality LONDON, GB / ACCESS Newswire / October 29, 2025 / New research from the Institute for Economics & Peace reveals that changing rainfall patterns are significantly amplifying conflict risks worldwide. The 2025 Ecological Threat Report (ETR), released today, finds conflict death rates are substantially higher in areas where rainfall is concentrating into fewer months, compared to regions where rain is spreading more evenly throughout the year.Ecological Threat Report 2025 Analysing Ecological Threats, Resilience & Peace Key Findings On average in areas where wet and dry seasons are becoming more extreme, there are four times as many conflict deaths as areas where it has decreased. In 2024, natural hazards triggered 45 million short-term internal displacements across 163 countries, the highest figure since at least 2008. Western Brazil, including parts of
Karbon-X Celebrates Major Milestone in Senegal Mangrove Restoration Project28.10.2025 14:00:00 EET | Press release
Planting completed across 7,000 hectares in partnership with Woodside Energy, advancing community-led climate action. DAKAR, SN / ACCESS Newswire / October 28, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to announce a significant milestone in its ABC Mangrove Project, one of West Africa's largest community-led restoration initiatives with the successful completion of planting across more than 7,000 hectares of mangroves along Senegal's coastline. Developed through ALLCOT, Karbon-X's project development and advisory arm (ALLCOT-A Karbon-X Company), and in partnership with Woodside Energy, the project is helping restore critical blue-carbon ecosystems that protect biodiversity, strengthen local economies, and capture carbon naturally from the atmosphere. Through this multi-year effort, thousands of local community members have been engaged in the planting and care of mangroves, creating new jobs, skills training, and sustainable income opportunities for wome
GoodData Brings AI-Native Data Intelligence to Financial Services28.10.2025 11:00:00 EET | Press release
Embeddable, compliant, and auditable AI agents unlock trusted automation for banks, insurers, and financial institutions. SAN FRANCISCO, CA / ACCESS Newswire / October 28, 2025 / GoodData, a leading analytics and data intelligence company, today unveiled new finance-focused applications for its composable AI platform, designed to tackle the industry's toughest challenges. By combining its AI Lake, AI Hub, and AI Apps into a single foundation for enterprise data intelligence, the next-generation platform gives financial institutions powerful tools to build and deploy AI agents. These agents can detect and investigate fraud in seconds with audit trails regulators can trust, keeping portfolios compliant in real time within industry guidelines. This streamlines regulatory reporting by compiling, checking, and submitting disclosures transparently, all while meeting strict standards for financial compliance, governance, and security. Purpose-built for finance The financial services sector fa
Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 202527.10.2025 15:00:00 EET | Press release
With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents - manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-D ISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics "ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom